Table 1:

Descriptive statistics of clinicopathological characteristics for pure DCIS based on the recurrence status in the (A) DC and (B) VC. The χ² p-values were used to determine if the differences in proportions were statistically significant.

A
Discovery Cohort Overall Clinical Characteristics
Baseline Characteristics	Recurrence-Free	Local Recurrence	p-value
Patient Age, n(%)
Age>50	87 (82.86)	22 (78.57)	0.6003
Age<=50	18 (17.14)	6 (21.43)
Tumor Size, n(%)
Size>16	51 (48.57)	15 (53.57)	0.6382
Size<=16	54 (51.43)	13 (46.43)
Grade, n(%)
High	97 (92.38)	21 (75.00)	0.0098
Mid and Low	8 (7.62)	7 (25.00)
Comedo Necrosis, n(%)
No	14 (13.33)	8 (28.57)	0.0538
Yes	91 (86.67)	20 (71.43)
Radiotherapy, n(%)
No	57 (54.29)	21 (75.00)	0.0480
Yes	48 (45.71)	7 (25.00)
Receptor Status, n(%)
ER/PR/HER2-Positive	3 (2.86)	2 (7.14)	0.6826
ER/PR-Positive and HER2-Negative	20 (19.05)	7 (25.00)
HER2-Positive	8 (7.62)	2 (7.14)
TNBC	9 (8.57)	1 (3.57)
Missing	65 (61.90)	16 (57.14)

B
Validation Cohort Overall Clinical Characteristics
Baseline Characteristics	Recurrence-Free	Local Recurrence	p-value
Patient Age, n(%)
Age>50	68 (71.58)	12 (50.00)	0.0442
Age<=50	27 (28.42)	12 (50.00)
Tumor Size, n(%)
Size>16	81 (85.26)	9 (37.50)	<0.0001
Size<=16	14 (14.74)	15 (62.50)
Grade, n(%)
High	47 (49.47)	12 (50.00)	0.9632
Mid and Low	48 (50.53)	12 (50.00)
Comedo Necrosis, n(%)
No	37 (38.95)	16 (66.67)	0.0146
Yes	58 (61.05)	8 (33.33)
Radiotherapy, n(%)
No	83 (87.37)	22 (91.67)	0.5593
Yes	12 (12.63)	2 (8.33)
Receptor Status, n(%)
ER/PR/HER2-Positive	9 (9.78)	4 (14.81)	0.4706
ER/PR-Positive and HER2-Negative	37 (40.22)	15 (55.56)
HER2-Positive	13 (14.13)	2 (7.41)
TNBC	6 (6.52)	1 (3.70)
Missing	27 (29.35)	5 (18.52)